

**INTERIM REPORT
for I-VI 2016
Medika d.d. Zagreb**

July 2016

Management interim report

Comment on the business results for the first six months of 2016

Medika d.d. („Company“) has realised total revenue in the first quarter of 2016 in amount of HRK 1 billion 299.9 million which is by 8.71% higher comparing to the same period of previous year.

Sales revenues which amount to HRK 1 billion 271.0 million for the first six months of 2016 are by 8.52% higher comparing to the same period of previous year.

Share of sales revenues in the total revenue is 97.78% while in the same period of previous year it was 97.95%.

Other operating revenues which amount to HRK 12.4 million are higher comparing to the same period of previous year by HRK 752 thousand, that is 6.47%. Since the share of other operating revenues in total revenue was only 0.97 % in the first six months of 2015, and in the first six months of 2016 is only 0.95%, this increase is not that significant.

Out of the total sales revenues, 99.88% revenues are generated on domestic market, while 0.12% is generated on the foreign market. This structure in the first six months of 2016 is almost on the same level comparing to the same period of previous year.

Material expenses amount to HRK 1 billion 201.0 million and are 8.25% higher comparing to the same period of previous year. Since the operating expenses are growing in lower percentage, share of material expenses in the operating expenses is higher for 0.02% comparing to the same period of previous year and amounts to 95.62%.

Employee expenses are higher by 2.68% comparing to the same period of previous year. Their share in the total expenses amounts to 2.10% while in the same period of previous year it amounted to 2.21%. Increase in employee expenses is influenced by higher number of employees.

Finance expenses have increased compared to the same period of previous year by HRK 1.1 million, which is 13.67%. Their share in the total expenses is by 0.03% higher compared to the same period of previous year and amounts 0.72%. This increase is the result of increase in interest expenses as a result of higher average indebtedness in the first six months of 2016 comparing to the same period of previous year.

Gross margin in the first six months of 2015 amounted to 6.58%, while in the first six months of 2016 amounts to 6.67%, which is increase of 0.09%. Increase is a result of larger increase in net sales revenue comparing to the increase in net cost of goods sold.

Gross profit (profit before taxation) amounts to HRK 34.8 million, while in the same period of previous year amounted to HRK 27.1 million, which is increase of HRK 7.7 million, or 28.31%. Higher gross profit is result of greater increase of total income (increase of 8.71% comparing to the same period of previous year) in relation to the increase of total expenses (increase of 8.26% comparing to the same period of previous year).

Operative earnings amount to HRK 27.4 million and are by HRK 5.1 million, which is 22.99%, higher comparing to the same period of previous year.

Realised net profit amounts to HRK 27.0 million.

Transactions with the related parties in the first six months of 2016 generated total net revenues in amount of HRK 139.0 million, which is 3.08% more of generated revenue in the same period of previous year when it amounted to HRK 134.9 million. Increase is a result of increase in number of pharmacy units in Prima Pharme Group.

Trade goods purchased from the related parties amount to HRK 113.8 million, while in the same period of previous year they amounted to HRK 78.3 million. Increase is result of increase in sales.

Total assets are by 6.87% higher comparing to the beginning of the year which is mostly influenced by increase of short term assets.

Long term assets are almost at the same level comparing to the beginning of the year. Long term intangible assets are lower comparing to the beginning of the year for HRK 665 thousand. Since there was no significant additions in 2016, decrease is a result of amortization. Long term tangible assets have decreased comparing to the beginning of the year for HRK 285 thousand. Looking at the structure of the long term tangible assets, assets under construction have increased, but due to the depreciation there was no significant change in total amount of long term tangible assets comparing to the beginning of the year.

Long term financial assets amounts to HRK 68.6 million and mostly relates to the investment in related parties.

Deferred tax assets are at the same level comparing to the beginning of the year.

Short term assets amount to HRK 1 billion 717.7 million and are by HRK 126.8 million, or 7.97%, higher comparing to the beginning of the year. In the structure of short term assets inventory and receivables have increased, while financial assets have decreased comparing to the beginning of the year.

Inventory has increased by HRK 9.8 million comparing to the beginning of the year which is a result of higher procurement due to the sales increase.

Total short term receivables amount to HRK 1 billion 281.8 million and are higher for HRK 161.5 million, which is 14.42%, comparing to the beginning of the year. Trade receivables and receivables from related parties amount to HRK 1 billion 278.2 million and have increased by 14.66% comparing to the beginning of the year.

Short term financial assets amount to HRK 159.1 million and relates to short term given loans. Comparing to the beginning of the year they have decreased for HRK 28.9 million due to the repayment of the given loans.

In equity there was change in treasury shares and capital reserves due to the granting of treasury shares to the management.

At the Regular General Assembly held on 30 June 2016, decision was passed to pay out the dividend to the shareholders in the amount of HRK 49.1 million. For this amount retained earnings have decreased and dividend payables have increased.

Short term liabilities amount to HRK 1 billion 557.1 million out of which HRK 1 billion 120.3 million relates to trade payables and liabilities to related parties and HRK 370.6 million to indebtedness (HRK 369.4 million to short term loans and HRK 1.2 million to finance lease).

Trade payables and liabilities to related parties are higher for HRK 57.1 million comparing to the beginning of the year.

Total loans liabilities of Medika amounts to HRK 383.3 million which is increase of HRK 51.9 million comparing to the beginning of the year. Out of the total loans liabilities, HRK 13.9 million relates to long term loans and HRK 369.4 million to short term loans. Short term indebtedness of Medika has increased for the liquidity purposes. All loans are in kuna and there is no exposure to foreign exchange risk at this balance sheet items.

Key events

Total pharmaceutical market in the first six months of 2016 has increased comparing to the same period of previous year. At the same time, sales of Medika have increased more comparing to the market increase, which resulted in higher market share in 2016.

In equity there was change in treasury shares and capital reserves due to the granting of treasury shares to the management.

At the Regular General Assembly held on 30 June 2016, decision was passed to pay out the dividend to the shareholders in the amount of HRK 49.1 million. For this amount retained earnings have decreased and dividend payables have increased.

Total indebtedness has increased for the liquidity purposes.

Expected future development of the Company

The Company will continue with its core business: distribution of medicinal products and medical devices will strongly develop operations with products that make the core business of the firm.

Treasury shares

As at 30.06.2016, Medika holds 1,302 treasury shares.

Subsidiaries and associates

The Company has subsidiaries Zdravstvena ustanova Ljekarne Prima Pharme and Put stinica d.o.o. Both subsidiaries are fully owned by the Company.

ZU Ljekarne Prima Pharme has 100% of ownership in subsidiaries ZU Ljekarne Delonga, ZU Ljekarne Ines Škoko, ZU Ljekarne Atalić, Ljekarna Mirela Klunić, Ljekarna Maja Mučaji, Ljekarna Mirja Bohunicki and associate ZU Ljekarne Jagatić in which it holds 49% of ownership.

Put stinica d.o.o. has 100% of ownership in subsidiary Primus nekretnine d.o.o.

Related parties

The company with major voting rights, Mavota d.o.o. owns 47.38% of the Company and has 49.52% of shares with voting rights.

Pliva Hrvatska d.o.o., Zagreb owns 25.32% of the Company and has 26.46% of the voting rights. Given the share in the ownership and business transactions with the Company, Pliva Hrvatska has significant influence on the current operations of the Company.

Financial risks and exposure to price risk, credit risk, liquidity and cash flow risk

Within financial risks, foreign exchange risk is significant. The Company's purchase of goods is partly realised on the foreign market. The Company is therefore exposed to foreign exchange risk arising from various changes in foreign exchange rates mainly linked to the EUR.

The Company has part of assets which are interest-bearing so the Company's income and operating cash flows are dependent of changes in market interest rates.

The Company's interest rate risk arises from short term and long term given loans and borrowings with variable interest rates. Borrowings with fixed interest rates expose the Company to the fair value interest rate risk exposure.

The Company does not use derivative instruments to actively hedge cash flow and fair value interest rate risk exposure. However, the Company continuously monitors changes in interest rates. Various scenarios are simulated taking into account refinancing, renewal of existing positions and alternative financing.

Price risk arises from a continuous decrease in the price of HZZO's List of medicinal products and administrative approach in determining prices and margins of medicinal products. To lower this risk, the Company focused on increase of variety of products which are not limited by law in respect of the price of the product.

Majority of the credit risk relates to trade receivables. Credit risk is higher when dealing with pharmacies, which have potential going concern issue. However, hospitals which have longer collection period do not have a going concern issue and collection issue.

The most significant risk within market risks is a long collection period of receivables, especially HZZO and HZZO related receivables. Therefore, a significant amount of working capital is not available what has an influence on cash flows and timely settlement of Medika liabilities.

As these receivables are directly or indirectly related to the receivables from the State institutions, the collection of these receivables should not be classified as a risk. This increases the need for additional financing, which increases finance expenses.

Jasminko Herceg, dipl.oec.
Director

² 
Medika d.d.
Z G R E B, Capriška 1

Appendix 1.

Reporting period:

1.1.2016.

to

30.6.2016.

Quarterly financial statements TFI-POD

Registration number (MB): 03209741

Identification number of company (MBS): 080027531

Personal identification number (OIB): 94818858923

Issuer: **MEDIKA d.d.**

Postal code and city: 10000 ZAGREB

Address: **CAPRAŠKA 1**e-mail: medika.uprava@medika.hrweb page: www.medika.hr

Code and name of municipality/city: 133 ZAGREB

Code and county name: 21 GRAD ZAGREB

Number of employees: 398
(end of reporting period)

Consolidated statements: NO

NKD code: 4646

Consolidated entities (according to IFRS):

Headquarters:

MB:

Bookkeeping service:

Contact person: **RADMILOVIĆ DIJANA**

(unosi se samo prezime i ime osobe za kontakt)

Telephone number: 012412551

Fax: 012371441

e-mail: medika.uprava@medika.hrName: **HERCEG JASMINKO**

(authorised person)

Documentation for publishing:

1. Financial statements (Balance sheet, Profit and loss account, Cash flow statements, Statements of changes in equity and Notes to financial statements)
2. Interim report,
3. Statement of Liability.

M.P.

Medika d.d.
ZAGREB, Capraška 1
(signature of authorised person)

BALANCE SHEET
balance as at 30.6.2016.

Issuer: MEDIKA d.d.			
Description	AOP mark	Previous period	Current period
1	2	3	4
ASSETS			
A) RECEIVABLES FOR SUBSCRIBED BUT NOT PAID-IN CAPITAL	001		
B) NON-CURRENT ASSETS (003+010+020+029+033)	002	251.520.971	251.643.209
I. INTANGIBLE ASSETS (004 to 009)	003	16.464.979	15.799.731
1. Research and development	004		
2. Concessions, patents, licences, trademarks, software and other rights	005	4.086.583	3.436.896
3. Goodwill	006	11.929.586	11.929.586
4. Advances for intangible assets	007		
5. Intangible assets under construction	008	448.810	433.249
6. Other intangible assets	009		
II. TANGIBLE ASSETS (011 to 019)	010	166.797.758	166.512.832
1. Land	011	18.232.855	18.232.856
2. Buildings	012	121.776.192	119.733.655
3. Equipment and machinery	013	11.674.075	11.409.942
4. Furniture, fittings and vehicles	014	12.107.472	10.169.337
5. Biological assets	015		
6. Advances for tangible assets	016		66.802
7. Tangible assets under construction	017	2.196.914	6.094.240
8. Other tangible assets	018	810.250	806.000
9. Investment property	019		
III. NON-CURRENT FINANCIAL ASSETS (021 to 028)	020	67.529.127	68.601.539
1. Investment in subsidiaries and associates	021	59.249.330	59.249.330
2. Loans to related parties	022		
3. Loans given to minority interest	023		
4. Loans given to participating parties	024		
5. Investment in securities	025		
6. Loans given, deposits and similar	026	8.279.797	9.352.209
7. Other non-current financial assets	027		
8. Investments at equity method	028		
IV. RECEIVABLES (030 to 032)	029	0	0
1. Receivables from related parties	030		
2. Receivables for credit sales	031		
3. Other receivables	032		
V. DEFERRED TAX ASSET	033	729.107	729.107
C) CURRENT ASSETS (035+043+050+058)	034	1.590.894.910	1.717.702.312
I. INVENTORY (036 To 042)	035	233.706.798	243.531.820
1. Raw material	036	143.024	114.722
2. Work in progress	037		
3. Finished products	038		
4. Trade goods	039	229.309.681	240.122.612
5. Advances for inventories	040	4.254.093	3.294.486
6. Non-current assets available for sale	041		
7. Biological assets	042		
II. RECEIVABLES (044 to 049)	043	1.120.266.105	1.281.776.052
1. Receivables from related parties	044	194.232.229	225.101.712
2. Trade receivables	045	920.527.020	1.053.062.259
3. Receivables from participating parties	046		
4. Receivables from employees	047	26.245	37.619
5. Receivables from the state and other institutions	048	3.393.564	993.342
6. Other receivables	049	2.087.047	2.581.120
III. CURRENT FINANCIAL ASSETS (051 to 057)	050	187.834.250	159.082.859
1. Investment in subsidiaries and associates	051		
2. Loans to related parties	052	160.000	260.000
3. Equity investments	053		
4. Loans given to participating parties	054		
5. Investment in securities	055		
6. Loans given, deposits and similar	056	187.674.250	158.822.859
7. Other financial assets	057		
IV. CASH IN BANK AND ON HAND	058	49.087.757	33.311.581
D) PREAPID EXPENSES AND ACCRUED INCOME	059	2.691.376	2.486.054
E) TOTAL ASSETS (001+002+034+059)	060	1.845.107.257	1.971.811.575
G) OFF BALANCE SHEET ITEMS	061	131.451.416	146.791.180

EQUITY AND LIABILITIES			
A) CAPITAL AND RESERVES (063+064+065+071+072+075+078)	062	419,161,170	393,580,243
I. SHARE CAPITAL	063	196,261,000	196,261,000
II. CAPITAL RESERVES	064	-8,652,683	-8,312,744
III. RESERVES FROM RETAINED EARNINGS (066+067-068+069+070)	065	89,677,247	85,852,773
1. Legal reserves	066	15,991,539	18,465,733
2. Reserves for treasury shares	067	51,286,174	48,811,980
3. Treasury shares	068	9,396,956	13,221,430
4. Statutory reserves	069		
5. Other reserves	070	31,796,490	31,796,490
IV. REVALUATION RESERVES	071		
V. RETAINED EARNINGS OR ACCUMULATED LOSS (073-074)	072	96,642,006	92,759,207
1. Retained earnings	073	96,642,006	92,759,207
2. Accumulated loss	074		
VI. PROFIT OR LOSS FOR THE PERIOD (076-077)	075	45,233,600	27,020,007
1. Profit for the period	076	45,233,600	27,020,007
2. Loss for the period	077		
VII. MAJORITY INTERESTS	078		
B) PROVISIONS (080 To 082)	079	802,829	802,829
1. Provisions for retirement, severance payment and similar	080	802,829	802,829
2. Tax provisions	081		
3. Other provisions	082		
C) NON-CURRENT LIABILITIES (084 to 092)	083	19,452,682	19,362,434
1. Liabilities to related parties	084		
2. Borrowings and deposits	085		
3. Liabilities to banks and other financial institutions	086	19,452,682	19,362,434
4. Liabilities for advances received	087		
5. Trade payables	088		
6. Liabilities for securities	089		
7. Liabilities to participating parties	090		
8. Other non-current liabilities	091		
9. Deferred tax liability	092		
D) CURRENT LIABILITIES (094 to 105)	093	1,405,566,921	1,557,142,643
1. Liabilities to related parties	094	114,785,187	131,993,940
2. Borrowings and deposits	095		
3. Liabilities to banks and other financial institutions	096	319,957,233	370,619,855
4. Liabilities for advances received	097	3,137,925	257,148
5. Trade payables	098	948,422,908	988,355,067
6. Liabilities for securities	099		
7. Liabilities to participating parties	100		
8. Liabilities to employees	101	6,434,707	4,633,816
9. Liabilities for taxes and contributions	102	9,314,729	9,839,477
10. Dividend payables	103	11,564	49,127,964
11. Liabilities for non-current assets available for sale	104		
12. Other current liabilities	105	3,502,668	2,315,376
E) DEFERRED INCOME AND ACCRUED EXPENSES	106	123,685	923,426
F) TOTAL EQUITY AND LIABILITIES (062+079+083+093+106)	107	1,845,107,287	1,971,811,575
G) OFF BALANCE SHEET ITEMS	108	131,451,416	146,791,180
SUPPLEMENT TO BALANCE SHEET (for consolidated financial statements)			
A) CAPITAL AND RESERVES			
1. Attributable to equity holders	109		
2. Attributable to minority interest	110		

Note 1.: Supplement to balance sheet is filled for consolidated financial statements.

PROFIT AND LOSS
for period from 1.1.2016. to 30.6.2016.

Issuer: MEDIKA d.d.

Description	AOP mark	Previous period		Current period	
		Cumulative	Quarter	Cumulative	Quarter
1	2	3	4	5	6
I. OPERATING REVENUES (112+113)	111	1.182.864.911	591.529.816	1.283.407.683	642.468.400
1. Revenues from sale	112	1.171.234.325	586.986.685	1.271.024.706	634.990.224
2. Other operating revenues	113	11.630.586	4.541.130	12.382.977	7.498.176
II. OPERATING EXPENSES (115+116+120+124+125+126+129+130)	114	1.160.562.966	577.007.602	1.255.978.862	626.053.688
1. Change in value of work in progress and finished goods	115				
2. Material expenses (117 to 119)	116	1.109.479.092	562.729.791	1.200.983.457	597.184.925
a) Raw materials	117	5.196.263	2.909.841	4.467.436	2.337.696
b) Cost of goods sold	118	1.094.162.193	544.415.743	1.186.198.665	589.137.073
c) Other expenses	119	10.120.636	5.404.207	10.327.356	5.710.154
3. Employee expenses (121 to 123)	120	25.672.940	12.979.585	26.362.165	13.253.162
a) Net salaries	121	15.121.764	7.648.025	15.497.341	7.767.258
b) Tax and contributions from salaries	122	6.861.170	3.441.345	7.172.063	3.628.366
c) Contributions on salaries	123	3.690.006	1.890.215	3.692.761	1.857.538
4. Depreciation and amortization	124	4.790.625	2.512.310	5.751.774	2.862.803
5. Other expenses	125	14.809.296	5.758.881	15.760.850	8.787.889
6. Impairment (127+128)	126	5.811.013	3.027.035	6.291.703	3.135.796
a) of non-current assets (financial assets excluded)	127				
b) of current assets (financial assets excluded)	128	5.811.013	3.027.035	6.291.703	3.135.796
7. Provisions	129			829.113	829.113
8. Other operating expenses	130				
III. FINANCE INCOME (132 to 136)	131	12.867.689	8.036.361	16.517.216	5.016.827
1. Interests, foreign exchanges and dividend from related parties	132			4.769	2.015
2. Interests, foreign exchanges and dividend from non-related parties	133	12.867.689	8.036.361	16.512.447	5.014.812
3. Share of profit from associate	134				
4. Unrealised gains	135				
5. Other financial income	136				
IV. FINANCE EXPENSES (138 to 141)	137	8.068.357	4.666.381	9.171.253	4.033.545
1. Interests, foreign exchanges and dividend from related parties	138				
2. Interests, foreign exchanges and dividend from non-related parties	139	8.068.357	4.666.381	9.171.253	4.033.545
3. Unrealised losses	140				
4. Other finance expenses	141				
V. SHARE OF PROFIT FROM ASSOCIATE	142				
VI. SHARE OF LOSS FROM ASSOCIATE	143				
VII. EXTRAORDINARY - OTHER INCOME	144				
VIII. EXTRAORDINARY - OTHER EXPENSES	145				
IX. TOTAL INCOME (111+131+142 + 144)	146	1.195.732.600	599.566.176	1.299.924.899	647.505.227
X. TOTAL EXPENSES (114+137+143 + 145)	147	1.168.631.323	581.673.983	1.265.150.115	630.087.233
XI. PROFIT OR LOSS BEFORE TAX (146-147)	148	27.101.277	17.892.193	34.774.784	17.417.994
1. Profit before tax (146-147)	149	27.101.277	17.892.193	34.774.784	17.417.994
2. Loss before tax (147-146)	150	0	0	0	0
XII. INCOME TAX	151	6.775.319	4.473.048	7.754.777	3.884.213
XIII. PROFIT OR LOSS FOR THE PERIOD (148-151)	152	20.325.958	13.419.145	27.020.007	13.533.781
1. Profit for the period (149-151)	153	20.325.958	13.419.145	27.020.007	13.533.781
2. Loss for the period (151-148)	154	0	0	0	0

SUPPLEMENT TO PROFIT AND LOSS (for consolidated financial statements)

XIV. PROFIT OR LOSS FOR THE PERIOD

1. Attributable to equity holders	155				
2. Attributable to minority interest	156				

OTHER COMPREHENSIVE INCOME REPORT (for IFRS reporting)

I. PROFIT OR LOSS FOR THE PERIOD (= 152)	157	20.325.958	13.419.145	27.020.007	13.533.781
II. OTHER COMPREHENSIVE PROFIT/LOSS BEFORE TAX (159 to 165)	158	0	0	0	0
1. Exchange differences on translation of foreign operations	159				
2. Changes in revaluation reserves for non-current tangible and intangible assets	160				
3. Profit or loss from revaluation of financial assets available for sale	161				
4. Gains or losses from efficient cash flow hedging	162				
5. Gains or losses from efficient hedge of net investment abroad	163				
6. Share in other comprehensive profit/loss of associates	164				
7. Actuarial gains/losses on defined benefit plans	165				
III. TAX ON OTHER COMPREHENSIVE INCOME FOR THE PERIOD	166				
IV. NET OTHER COMPREHENSIVE PROFIT OR LOSS FOR THE PERIOD (158-166)	167	0	0	0	0
V. COMPREHENSIVE PROFIT OR LOSS FOR THE PERIOD (157+167)	168	20.325.958	13.419.145	27.020.007	13.533.781

APPENDIX to Other comprehensive income report (to be filled for consolidated financial statements)

VI. COMPREHENSIVE PROFIT OR LOSS

1. Attributable to equity holders	169				
2. Attributable to minority interest	170				

STATEMENT OF CASH FLOW - Indirect method
for period from 1.1.2016. to 30.6.2016.

Issuer: MEDIKA d.d.			
Description	AOP mark	Previous period	Current period
1	2	3	4
CASH FLOW FROM OPERATING ACTIVITIES			
1. Profit before tax	001	27.101.277	34.774.784
2. Depreciation and amortisation	002	4.790.625	5.751.774
3. Increase of current liabilities	003	54.303.445	100.913.100
4. Decrease of current receivables	004		
5. Decrease of inventories	005		
6. Other increase of cash flow	006		
I. Total increase of cash flow from operating activities (001 to 006)	007	86.195.347	141.439.658
1. Decrease of current liabilities	008		
2. Increase of current receivables	009	89.694.006	161.509.917
3. Increase of inventories	010	4.536.257	9.825.021
4. Other decrease of cash flow	011	66.009.593	36.152.770
II. Total decrease of cash flow from operating activities (008 to 011)	012	160.239.856	207.487.708
A1) NET INCREASE OF CASH FLOW FROM OPERATING ACTIVITIES (007-012)	013	0	0
A2) NET DECREASE OF CASH FLOW FROM OPERATING ACTIVITIES (012-007)	014	74.044.509	66.048.050
CASH FLOW FROM INVESTING ACTIVITIES			
1. Proceeds from sale of tangible and intangible assets	015	531.481	714.157
2. Proceeds from sale of equity and debt securities	016		
3. Interest received	017	7.202.474	8.308.458
4. Dividends received	018		
5. Other proceeds from investing activities	019		
III. Total proceeds from investing activities (015 to 019)	020	7.733.955	9.022.615
1. Purchase of tangible and intangible assets	021	8.062.079	4.909.159
2. Purchase of equity and debt securities	022		
3. Other purchases resulting from investing activities	023		
IV. Total purchases resulting from investing activities (021 to 023)	024	8.062.079	4.909.159
B1) NET INCREASE OF CASH FLOW FROM INVESTING ACTIVITIES (020-024)	025	0	4.113.456
B2) NET DECREASE OF CASH FLOW FROM INVESTING ACTIVITIES (024-020)	026	328.124	0
CASH FLOW FROM FINANCING ACTIVITIES			
1. Proceeds from issuance of equity and debt securities	027		
2. Proceeds from borrowings	028	178.114.751	442.000.000
3. Other proceeds from financing activities	029		
V. Total proceeds from financing activities (027 to 029)	030	178.114.751	442.000.000
1. Repayments of borrowings	031	71.877.083	390.087.500
2. Dividends paid	032		
3. Repayments of finance lease	033	983.291	1.229.549
4. Purchase of treasury shares	034		4.524.533
5. Other purchases resulting from financing activities	035		
VI. Ukupno novčani izdaci od financijskih aktivnosti (031 to 035)	036	72.860.374	395.841.582
C1) NET INCREASE OF CASH FLOW FROM FINANCING ACTIVITIES (030-036)	037	105.254.377	46.158.418
C2) NET DECREASE OF CASH FLOW FROM FINANCING ACTIVITIES (036-030)	038	0	0
Total increase of cash flow (013 – 014 + 025 – 026 + 037 – 038)	039	30.881.744	0
Total decrease of cash flow (014 – 013 + 026 – 025 + 038 – 037)	040	0	15.776.176
Cash and cash equivalents at beginning of the period	041	65.109.276	49.087.757
Increase of cash and cash equivalents	042	30.881.744	
Decrease of cash and cash equivalents	043		15.776.176
Cash and cash equivalents at end of the period	044	95.991.020	33.311.581

STATEMENT OF CHANGES IN EQUITY
for period from **1.1.2016.** to **30.6.2016.**

Description	AOP mark	Previous period	Current period
1	2	3	4
1. Share capital	001	196.261.000	196.261.000
2. Capital reserves	002	-8.652.683	-8.312.744
3. Reserves from retained earnings	003	89.677.247	86.852.773
4. Retained earnings or accumulated loss	004	96.642.006	92.759.207
5. Profit or loss for the period	005	45.233.600	27.020.007
6. Revaluation of tangible assets	006		
7. Revaluation of intangible assets	007		
8. Revaluation of financial assets available for sale	008		
9. Other revaluation	009		
10. Total capital and reserves (AOP 001 to 009)	010	419.161.170	393.580.243
11. Foreign exchanges from the foreign investments	011		
12. Current and deferred tax (part)	012		
13. Cash flow hedge	013		
14. Changes of accounting policies	014		
15. Correction of material mistakes from previous period	015		
16. Other changes of equity	016		
17. Total increase or decrease of equity (AOP 011 to 016)	017	0	0
17 a. Pripisano imateljima kapitala matice	018		
17 b. Attributable to minority interest	019		

Balances that decrease equity are presented with the minus
Data in AOP 001 to 009 are presented as the balance as at balance sheet date

Zagreb, 29 July 2016

Pursuant to the articles 401. to 410. of the Capital market Law (Official Gazette 88/08, 146/08, 74/09, 54/13, 159/13, 18/15 and 110/15) Director Jasminko Herceg provides

STATEMENT OF LIABILITY FOR PREPARING FINANCIAL STATEMENTS OF ISSUER

Unaudited unconsolidated and consolidated financial statements of Medika d.d. have been prepared pursuant to the International Financial Reporting Standards (IFRS) and Croatian Accounting Law.

Unaudited unconsolidated and consolidated financial statements for the period 01 January to 30 June 2016 present complete and fair view of assets and liabilities, profit and loss, financial position and operations of the Company and the Group.

The interim management report for the unaudited financial statements for the period 01 January to 30 June 2016 presents true and fair presentation of development and results of the operations and position of the Company and the Group with description of significant risks and uncertainties for the Company and the Group.

Jasminko Herceg
Director

 **Medika** d.d.
Z A G R E B, Capraška 1